Skip to main content

Advertisement

Table 1 Locally advanced rectal adenocarcinoma patients analysed by gene expression microarray.

From: APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profiling

Patient Treatment1 Stage at Diagnosis2 Diagnostic biopsy grade & histology Diagnostic biopsy cellularity3 Surgical biopsy grade & histology Surgical biopsy cellularity3 Pathological stage4
CRT1 CRT T2N1 M0 moderately differentiated adenocarcinoma 60% poorly differentiated adenocarcinoma 60% T3N2
CRT2 CRT T3N1 M0 moderately differentiated adenocarcinoma 60% moderately differentiated adenocarcinoma 60% T3N1
CRT3 CRT T3N0 M0 moderately differentiated adenocarcinoma 60% moderately differentiated adenocarcinoma 50% T3N0
CRT4 CRT T4N1 M0 moderately differentiated adenocarcinoma 50% moderately differentiated adenocarcinoma 50% T2N0
RT1 RT T2N0 M0 moderately differentiated adenocarcinoma 60% moderately differentiated adenocarcinoma 60% T3N0
RT2 RT T2N1 M0 moderately differentiated adenocarcinoma 60% moderately differentiated adenocarcinoma 60% T2N1
RT3 RT T2N0 M0 moderately differentiated adenocarcinoma 50% moderately differentiated adenocarcinoma 60% T3N2
RT4 RT T2N0 M0 moderately differentiated adenocarcinoma 60% moderately differentiated adenocarcinoma 60% T3N0
CON1 None T3N1 M0 moderately differentiated adenocarcinoma 75% moderately differentiated adenocarcinoma 70% T3N1
CON2 None T2N1 M0 moderately differentiated adenocarcinoma 50% moderately differentiated adenocarcinoma 50% T3N1
  1. 1 CRT = neoadjuvant concurrent chemoradiotherapy; RT = Short course pre-operative radiotherapy. 2 MRI and clinical stage. 3 % Tumour versus normal cells in biopsy profiled. 4 Pathological stage post-preoperative therapy